Navigation Links
China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
Date:11/23/2007

one-time loss from discontinue operations of $2 million during the same nine month period in 2006. Therefore, the net loss for the nine month period ending September 30, 2007 was $11.7 million versus a net loss of $1.9 million for the same period one year ago.

Balance Sheet and Debt Conversion

As of September 30, 2007, total assets were $34.4 million and total liabilities plus minority interest were $36.1 million. Subsequent to the quarter, the Company entered into an agreement on November 19, 2007, under which the principal amount of the $11.5 million Loan owed to RimAsia in connection with the Enshi acquisitions plus unpaid interest of $1,008,534, which totals $12,508,534 will be conditionally converted in full into 6,185,607 shares of senior redeemable convertible preferred shares of the Company. Thus the above listed liabilities would be decreased $12.5 million while the book value of the Company would increase by the same amount. Therefore current shareholder equity of negative $1.7 million, would improve to $10.8 million or $.30 per share based on the 36.5 million shares currently outstanding, and $.22 per fully diluted share with the preferred included.

These new preferred shares have an effective conversion price of $1.011. Additionally, the exercise price of $1.375 for the 12 million existing warrants exercisable into the Company's common stock previously issued to and currently held by RimAsia in connection with the extension of the Loan financing will be lowered to $1.26 per share and the term of the Existing Warrants extended to 4.5 years from the closing date. This is conditioned on the Company signing a letter of intent for acquisition of a new company or for the injection of the remaining 49% equity stake of Erye not already owned by the Company before January 15, 2008, having such acquisition closed before June 30, 2008.

Subsequent Events -- New Drug Development Agreement

Subsequent to the end of our third quarter o
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... CITY , Nov. 18, 2014  Great Basin Scientific, ... today announced that the management will host a conference call ... and development programs on Thursday, Nov. 20, at 4:30 pm ... we have made since the Company,s recent IPO and would ... Great Basin,s management," said Ryan Ashton , President and ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today the formation of a ... guidance to the Company as it advances the ... for the treatment of cutaneous T-cell lymphoma (CTCL), ...
(Date:11/15/2014)... Collaborative Consulting, a privately held, employee-based ... of the Boston Globe’s “Top Places to Work 2014”. ... Massachusetts to receive the honor. , The Boston Globe’s ... of their most valuable resource: the people who work ... are based on an array of criteria, including the ...
(Date:11/15/2014)... November 14, 2014 The ... announced today that the society’s Governing Board has ... Edwards Lifesciences chief scientific officer and Dr. Charles ... officer, Abbott Vascular. Mr. Rowe and Dr. ... device development experts. , Dr. Nabil Dib, ...
Breaking Biology Technology:Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders 2
... Group in North America with this Elevated Partner ... ... an Oracle System,Integrator, today announced it has achieved Oracle Certified Advantage,Partner status ... the highest level in the Oracle PartnerNetwork -- BIAS had,to demonstrate superior ...
... for the Long-Term Care Channel, BASKING ... wholly owned subsidiary of Millennium Biotechnologies,Group, Inc. ... the initial,$200,000.00 monthly shipment from Millennium Biotechnologies, ... the previously announced $20,000,000,Five- year exclusive Purchase ...
... Life Sciences R&D to ... Ensure Continued Growth, ... Authority (EDA) announced today that Tris Pharma, Inc. will,expand its ... bonds issued under the state,s Edison Innovation,Fund. Representatives from the ...
Cached Biology Technology:BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 3Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 3Edison Innovation Fund Helps Tris Pharma Expand 2Edison Innovation Fund Helps Tris Pharma Expand 3
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... position is a determinant of antiretroviral treatment effectiveness during ... even among subjects with high rates of drug adherence, ... issue of the Journal of Psychosomatic Research. The ... Harvard School of Public Health (HSPH), Massachusetts General Hospital, ...
... of rotten meat on the premises of a wholesaler in ... grocery stores everywhere is not to be underestimated, the importance ... reliable measurement methods that enable large numbers of samples to ... place in order to make comprehensive monitoring a reality. In ...
... of the GSF National Research Center for Environment ... Centres) the group is continuing to search for cellular ... a prion infection. In collaboration with colleagues from the ... the group used micro-array technologies micro-arrays are ...
Cached Biology News:Socioeconomic position associated with effectiveness of HIV drugs 2New method reveals substances on surfaces of any kind 2Prions and retroviruses -- an unholy alliance? 2
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
Biology Products: